Corline Biomedical AB (CLBIO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.072x

Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of -0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.76 Million ≈ $-727.59K USD) by net assets (Skr93.76 Million ≈ $10.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Corline Biomedical AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Corline Biomedical AB - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
IBKS No. 15 Special Purpose Acquisition Co. Ltd. KQ:373200	-0.245x
Energia Latina SA SN:ENLASA	0.077x
Beammwave AB B ST:BEAMMW-B	-0.048x
Marygold Companies Inc NYSE MKT:MGLD	-0.040x
Manhattan Bridge Capital Inc NASDAQ:LOAN	0.029x
Pratama Widya Tbk Pt JK:PTPW	0.027x
Sungchang Hold KO:000180	-0.004x
Consus Enerji Isletmeciligi ve Hizmetleri AS IS:CONSE	0.196x

Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see CLBIO stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr93.76 Million ≈ $10.09 Million	Skr-17.69 Million ≈ $-1.90 Million	-0.189x	-89.81%
2024-12-31	Skr86.91 Million ≈ $9.35 Million	Skr-8.64 Million ≈ $-929.69K	-0.099x	-1146.88%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	Skr886.00K ≈ $95.35K	0.009x	+113.92%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	Skr-6.45 Million ≈ $-694.34K	-0.068x	-30.12%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	Skr-4.83 Million ≈ $-520.32K	-0.052x	+46.16%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	Skr-5.07 Million ≈ $-545.18K	-0.097x	+58.27%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	Skr-13.84 Million ≈ $-1.49 Million	-0.233x	-212.44%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	Skr-4.10 Million ≈ $-441.66K	-0.075x	+31.11%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	Skr-4.98 Million ≈ $-535.71K	-0.108x	+41.76%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	Skr-7.21 Million ≈ $-776.02K	-0.186x	+6.53%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-4.23 Million ≈ $-455.34K	-0.199x	+52.91%
2014-12-31	Skr5.48 Million ≈ $590.25K	Skr-2.32 Million ≈ $-249.55K	-0.423x	-22.53%
2013-12-31	Skr8.00 Million ≈ $860.60K	Skr-2.76 Million ≈ $-296.95K	-0.345x	--

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$48.93 Million

Skr454.64 Million SEK

Market Cap Rank

#22035 Global

#414 in Sweden

Share Price

Skr17.75

Change (1 day)

-0.84%

52-Week Range

Skr10.00 - Skr21.20

All Time High

Skr28.20